tetano
Editor, Senior Moderator
Eur Respir Rev
. 2023 Jul 12;32(169):220254.
doi: 10.1183/16000617.0254-2022. Print 2023 Sep 30. SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis
J Daniel Kelly[SUP] 1 [/SUP], Tristan Curteis[SUP] 2 [/SUP], Aaditya Rawal[SUP] 3 [/SUP], Molly Murton[SUP] 4 [/SUP], Laura J Clark[SUP] 2 [/SUP], Zarena Jafry[SUP] 3 [/SUP], Rikisha Shah-Gupta[SUP] 5 [/SUP], Mark Berry[SUP] 5 [/SUP], Aprille Espinueva[SUP] 6 [/SUP], Linda Chen[SUP] 6 [/SUP], Mazin Abdelghany[SUP] 6 [/SUP], Daniel A Sweeney[SUP] 7 [/SUP], Jennifer K Quint[SUP] 8 [/SUP]
Affiliations
Background: Many individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection experience post-acute sequelae of SARS-CoV-2 infection (PASC), sometimes referred to as "long COVID". Our objective was to conduct a systematic literature review and meta-analysis to identify PASC-associated symptoms in previously hospitalised patients and determine the frequency and temporal nature of PASC.
Methods: Searches of MEDLINE, Embase, Cochrane Library (2019-2021), World Health Organization International Clinical Trials Registry Platform and reference lists were performed from November to December 2021. Articles were assessed by two reviewers against eligibility criteria and a risk of bias tool. Symptom data were synthesised by random effects meta-analyses.
Results: Of 6942 records, 52 studies with at least 100 patients were analysed; ∼70% were Europe-based studies. Most data were from the first wave of the pandemic. PASC symptoms were analysed from 28 days after hospital discharge. At 1-4 months post-acute SARS-CoV-2 infection, the most frequent individual symptoms were fatigue (29.3% (95% CI 20.1-40.6%)) and dyspnoea (19.6% (95% CI 12.8-28.7%)). Many patients experienced at least one symptom at 4-8 months (73.1% (95% CI 44.2-90.3%)) and 8-12 months (75.0% (95% CI 56.4-87.4%)).
Conclusions: A wide spectrum of persistent PASC-associated symptoms were reported over the 1-year follow-up period in a significant proportion of participants. Further research is needed to better define PASC duration and determine whether factors such as disease severity, vaccination and treatments have an impact on PASC.
. 2023 Jul 12;32(169):220254.
doi: 10.1183/16000617.0254-2022. Print 2023 Sep 30. SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis
J Daniel Kelly[SUP] 1 [/SUP], Tristan Curteis[SUP] 2 [/SUP], Aaditya Rawal[SUP] 3 [/SUP], Molly Murton[SUP] 4 [/SUP], Laura J Clark[SUP] 2 [/SUP], Zarena Jafry[SUP] 3 [/SUP], Rikisha Shah-Gupta[SUP] 5 [/SUP], Mark Berry[SUP] 5 [/SUP], Aprille Espinueva[SUP] 6 [/SUP], Linda Chen[SUP] 6 [/SUP], Mazin Abdelghany[SUP] 6 [/SUP], Daniel A Sweeney[SUP] 7 [/SUP], Jennifer K Quint[SUP] 8 [/SUP]
Affiliations
- PMID: 37437914
- DOI: 10.1183/16000617.0254-2022
Background: Many individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection experience post-acute sequelae of SARS-CoV-2 infection (PASC), sometimes referred to as "long COVID". Our objective was to conduct a systematic literature review and meta-analysis to identify PASC-associated symptoms in previously hospitalised patients and determine the frequency and temporal nature of PASC.
Methods: Searches of MEDLINE, Embase, Cochrane Library (2019-2021), World Health Organization International Clinical Trials Registry Platform and reference lists were performed from November to December 2021. Articles were assessed by two reviewers against eligibility criteria and a risk of bias tool. Symptom data were synthesised by random effects meta-analyses.
Results: Of 6942 records, 52 studies with at least 100 patients were analysed; ∼70% were Europe-based studies. Most data were from the first wave of the pandemic. PASC symptoms were analysed from 28 days after hospital discharge. At 1-4 months post-acute SARS-CoV-2 infection, the most frequent individual symptoms were fatigue (29.3% (95% CI 20.1-40.6%)) and dyspnoea (19.6% (95% CI 12.8-28.7%)). Many patients experienced at least one symptom at 4-8 months (73.1% (95% CI 44.2-90.3%)) and 8-12 months (75.0% (95% CI 56.4-87.4%)).
Conclusions: A wide spectrum of persistent PASC-associated symptoms were reported over the 1-year follow-up period in a significant proportion of participants. Further research is needed to better define PASC duration and determine whether factors such as disease severity, vaccination and treatments have an impact on PASC.